Tag: Biopharmaceutical

Bristol Myers Squibb is the global biopharmaceutical company that currently makes Breyanzi, a highly specialized and personalized CAR T-cell therapy. The medication's journey to market is the result of a series of corporate acquisitions, with its origins tracing back to the biotechnology company Juno Therapeutics.

As of late 2025, there is no generic for Fasenra injection, because it is a biologic medication, not a traditional chemical drug. Instead of generics, complex biologics like Fasenra (benralizumab) may one day have "biosimilars," but these are not yet approved.